From 80317d73241ae2c6f84caefa7c1fb5bdef5d3cd9 Mon Sep 17 00:00:00 2001 From: jonniec4989319 Date: Fri, 3 Apr 2026 03:40:23 +0800 Subject: [PATCH] Add Testosterone Replacement Therapy for Male Hypogonadism --- Testosterone-Replacement-Therapy-for-Male-Hypogonadism.md | 7 +++++++ 1 file changed, 7 insertions(+) create mode 100644 Testosterone-Replacement-Therapy-for-Male-Hypogonadism.md diff --git a/Testosterone-Replacement-Therapy-for-Male-Hypogonadism.md b/Testosterone-Replacement-Therapy-for-Male-Hypogonadism.md new file mode 100644 index 0000000..dd46011 --- /dev/null +++ b/Testosterone-Replacement-Therapy-for-Male-Hypogonadism.md @@ -0,0 +1,7 @@ +
+
Currently published studies have not demonstrated an increased risk of biochemical cancer recurrence in post-RP patients who are on [testosterone purchase](https://smartcampus-seskoal.id/streaming/@emiliakuntz04?page=about) therapy, nor does it define the optimal timing for commencement of testosterone therapy. It is the opinion of this Panel that until there is definitive evidence demonstrating that testosterone therapy is not safe for use in prostate cancer patients, the decision to commence testosterone therapy in men with a history of prostate cancer is a negotiated decision based on the perceived potential benefit of treatment. Given the reproductive profile of the study population, the spermatogenesis results might not be generalizable to patients with [buy testosterone gel](https://www.fepp.org.ec/kristallyng407) deficiency.332A study of 66 males who presented with infertility while on exogenous [buy testosterone gel](http://120.201.125.140:3000/robertopreraue/533789.58.50.249/wiki/Buy-Testosterone-Enanthate-online%2C-cheap-injection-for-sale) therapy revealed several interesting findings.333 The authors used a total motile sperm count (TMSC) of 5 million as the benchmark for spermatogenesis recovery. Patients with testosterone deficiency who maintain [buy testosterone without prescription](https://rentry.co/32181-primary-testicular-failure-endotext-ncbi-bookshelf) levels in the normal range while on testosterone therapy should have their PSA levels tested, utilizing a shared decision-making approach, in accordance with the AUA's Early Detection of Prostate Cancer Guideline. In patients who have two PSA levels at baseline that raise suspicion for the presence of prostate cancer, a more formal evaluation, potentially including reflex testing (e.g., 4K or phi), and prostate biopsy with/without MRI, should be considered before initiating testosterone therapy. +However, there’s no official consensus on healthy testosterone levels. Estradiol levels shall be evaluated after 6 months of treatment or after amenorrhea is installed. It is recommended that testosterone levels be measured 7 to 10 days after intramuscular testosterone esters injection, nearby the nadir levels or at any time after 1 week of transdermal androgen use. Other comorbidities, such as sleep apnea, impairment in lipid profile, insulin sensitivity reduction, polycythemia, venous thromboembolism, arterial hypertension and atherosclerosis, can be worsen or be initiated by the chronic use of androgen therapy, potentially increasing cardiovascular risk.16 However, the use of different [testosterone for sale](https://www.ip-exhibitions.net/employer/testosterone-for-sale-buy-testosterone-online-legally/) formulations does not seem to affect the systemic arterial blood pressure, the carotid intima media layer thickness nor the deposition of calcium in the coronary arteries. Mammary tissue is another target that seems to have its composition altered by testosterone therapy.9 Histological analyses of mammary tissues from androgen treated transgender men submitted to mastectomy during the transsexualization process have evidenced a substantial reduction in glandular and adipose tissues and an increment in the fibrous connective tissue. In one study, all the evaluated samples indicated inactive endometrium, similar to the endometrium seen in postmenopausal women but in another study, only half of the patients presented atrophic endometrium, while in the other half a proliferative endometrium was found even after 2 to 9 months of androgenic therapy.9 +A meta-analysis of RCTs developed in support of this guideline indicate that there is no significant difference in MACE in men on testosterone therapy when compared to placebo. RCTs have failed to categorically define if testosterone therapy increases the incidence of MACE when compared to placebo. A discussion regarding the benefit of stopping [testosterone online pharmacy](http://109.74.60.187:5001/rosaurafleck5) therapy should include the possibility of a decline in PSA. PSA recurrence in men on [order testosterone online](https://geniusactionblueprint.com/@vwfdamon643706?page=about) therapy should be evaluated in the same fashion as untreated men. There are limited data in men on active surveillance who are candidates for [buy testosterone enanthate](https://git.gasshog.fr/twwnathaniel33) therapy. +In general, smaller dosages at more frequent intervals are preferred over high, less frequent administrations to limit the duration of time spent outside (above or below) the normal reference range. The optimal dosing strategy has not been defined for short-acting IM [order testosterone online](http://104.254.131.244:3000/launagreenberg) preparations. Mean testosterone values over a 7-day time period were 1,659, 896, and 422 ng/dL for IM testosterone SQ 100, and SQ 50, respectively. The half-life for IM testosterone was also shorter at 173 hours versus 240 hours for SQ testosterone. +Testosterone therapy should be initiated only after two morning total serum testosterone measurements show decreased levels, and all patients should be counseled on the potential risks and benefits before starting therapy. Although prior studies suggested that testosterone replacement therapy increased the risk of cardiovascular disease, a large, randomized trial showed that it does not increase the risk of myocardial infarction or stroke, even in patients at high risk. Testosterone deficiency, or [musicsound.ca](https://www.musicsound.ca/arasadlier2675) male hypogonadism, is a clinical syndrome that can be defined as persistently low serum testosterone levels in the setting of symptoms consistent with testosterone deficiency. In men.65 years who have symptoms or conditionssuggestive of [buy testosterone without prescription](https://gitea.myat4.com/collinwakehurs) deficiency (such as low libido or unexplained anemia) and consistentlyand unequivocally low morning testosterone concentrations, we suggest that clinicians offertestosterone therapy on an individualized basis after explicit discussion of the potential risks andbenefits. +
\ No newline at end of file